FI972202A - Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun - Google Patents

Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun Download PDF

Info

Publication number
FI972202A
FI972202A FI972202A FI972202A FI972202A FI 972202 A FI972202 A FI 972202A FI 972202 A FI972202 A FI 972202A FI 972202 A FI972202 A FI 972202A FI 972202 A FI972202 A FI 972202A
Authority
FI
Finland
Prior art keywords
androstanes
pregnanes
gaba receptors
allosteric modification
allosteric
Prior art date
Application number
FI972202A
Other languages
English (en)
Swedish (sv)
Other versions
FI972202A0 (fi
Inventor
Nancy C Lan
Kelvin W Gee
Michael B Bolger
Hasan Tahir
Robert Purdy
Ravindra B Upasani
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of FI972202A0 publication Critical patent/FI972202A0/fi
Publication of FI972202A publication Critical patent/FI972202A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI972202A 1994-11-23 1997-05-23 Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun FI972202A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34692694A 1994-11-23 1994-11-23
PCT/US1995/015210 WO1996016076A1 (en) 1994-11-23 1995-11-22 Androstane and pregnane series for allosteric modulation of gaba receptor

Publications (2)

Publication Number Publication Date
FI972202A0 FI972202A0 (fi) 1997-05-23
FI972202A true FI972202A (fi) 1997-07-17

Family

ID=23361616

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972202A FI972202A (fi) 1994-11-23 1997-05-23 Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun

Country Status (27)

Country Link
EP (1) EP0808325B1 (fi)
JP (1) JPH10509458A (fi)
KR (1) KR100394548B1 (fi)
CN (1) CN1171114A (fi)
AP (1) AP653A (fi)
AT (1) ATE198753T1 (fi)
AU (1) AU707486B2 (fi)
BR (1) BR9509764A (fi)
CA (1) CA2205919A1 (fi)
CZ (1) CZ292881B6 (fi)
DE (1) DE69519945T2 (fi)
DK (1) DK0808325T3 (fi)
ES (1) ES2155543T3 (fi)
FI (1) FI972202A (fi)
GE (1) GEP20002033B (fi)
GR (1) GR3035562T3 (fi)
HU (1) HUT77087A (fi)
IL (1) IL116108A (fi)
IS (1) IS4488A (fi)
MX (1) MX9703826A (fi)
NO (1) NO308950B1 (fi)
NZ (1) NZ298567A (fi)
PL (1) PL182898B1 (fi)
PT (1) PT808325E (fi)
RU (1) RU2176248C2 (fi)
UA (1) UA48154C2 (fi)
WO (1) WO1996016076A1 (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
BR9608592A (pt) * 1995-06-06 1999-06-29 Cocensys Inc Esteróides neuroativos da série do androstano e do pregnano
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
AU756001B2 (en) 1998-03-11 2003-01-02 Umecrine Mood Ab Epiallopregnanolone in the treatment of CNS disorders
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE60020732T2 (de) 1999-12-20 2006-05-11 Kerkhof, Nicholas J., Rio Vista Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2097437B1 (en) 2006-11-21 2015-05-27 Umecrine Cognition AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
CN103819525A (zh) * 2008-05-20 2014-05-28 梅克芳股份公司 甾族化合物
CN103880909A (zh) * 2008-05-20 2014-06-25 梅克芳股份公司 甾族化合物
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010282570B2 (en) * 2009-08-13 2014-04-24 Marinus Pharmaceuticals, Inc. Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone)
AU2011205821B2 (en) 2010-01-14 2013-07-25 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
CA2843436A1 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
US20150158903A1 (en) * 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2852057C (en) 2011-10-14 2022-06-07 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
BR112014018110B1 (pt) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
KR102305359B1 (ko) * 2012-08-21 2021-09-24 세이지 테라퓨틱스, 인크. 간질 또는 간질지속 상태를 치료하는 방법
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
PT3461834T (pt) 2013-03-13 2021-09-10 Sage Therapeutics Inc Esteroides neuroativos
LT2986624T (lt) 2013-04-17 2020-07-10 Sage Therapeutics, Inc. Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) * 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
SG10201802389SA (en) 2013-04-17 2018-04-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
AU2014290400B2 (en) 2013-07-19 2019-12-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR102612943B1 (ko) 2014-10-16 2023-12-13 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
EP3753927B1 (en) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
PT3224269T (pt) 2014-11-27 2020-06-01 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios do snc
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN108135911B (zh) 2015-07-06 2021-06-25 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN109414444A (zh) 2016-03-08 2019-03-01 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4302764A2 (en) 2016-07-11 2024-01-10 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2019140272A1 (en) * 2018-01-12 2019-07-18 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
US11542296B2 (en) 2018-04-23 2023-01-03 The Texas A&M University System Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders
EP3864022B1 (en) 2018-10-12 2023-09-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
US20230322846A9 (en) 2018-12-05 2023-10-12 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN111410673A (zh) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
BR112021026445A2 (pt) * 2019-06-27 2022-03-08 Sage Therapeutics Inc Composições e métodos para tratar distúrbios de cns
JP2023518411A (ja) * 2020-03-18 2023-05-01 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその使用方法
AU2022331486A1 (en) * 2021-08-20 2024-03-07 Md Imdadul H. KHAN Allopregnanolone analogues for hiv viremia and neurotoxicity protection
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
CA2118938A1 (en) * 1991-09-13 1993-04-01 Kelvin W. Gee Novel gabaa receptor with steroid binding sites
US5371077A (en) * 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep

Also Published As

Publication number Publication date
AP9700998A0 (en) 1997-07-31
GR3035562T3 (en) 2001-06-29
EP0808325A4 (fi) 1997-12-17
GEP20002033B (en) 2000-04-10
IL116108A0 (en) 1996-01-31
IS4488A (is) 1997-05-23
PL182898B1 (pl) 2002-03-29
NZ298567A (en) 2000-01-28
FI972202A0 (fi) 1997-05-23
ATE198753T1 (de) 2001-02-15
NO972320L (no) 1997-07-23
DE69519945D1 (de) 2001-02-22
AU707486B2 (en) 1999-07-08
AP653A (en) 1998-07-21
CZ155397A3 (cs) 1998-03-18
DK0808325T3 (da) 2001-01-29
AU4408596A (en) 1996-06-17
IL116108A (en) 2002-08-14
JPH10509458A (ja) 1998-09-14
BR9509764A (pt) 1998-07-07
CA2205919A1 (en) 1996-05-30
HUT77087A (hu) 1998-03-02
EP0808325B1 (en) 2001-01-17
ES2155543T3 (es) 2001-05-16
CZ292881B6 (cs) 2003-12-17
RU2176248C2 (ru) 2001-11-27
WO1996016076A1 (en) 1996-05-30
UA48154C2 (uk) 2002-08-15
DE69519945T2 (de) 2001-06-07
NO972320D0 (no) 1997-05-21
PL320416A1 (en) 1997-09-29
EP0808325A1 (en) 1997-11-26
PT808325E (pt) 2001-06-29
MX9703826A (es) 1998-02-28
NO308950B1 (no) 2000-11-20
KR100394548B1 (ko) 2004-02-05
CN1171114A (zh) 1998-01-21

Similar Documents

Publication Publication Date Title
FI972202A (fi) Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
DE69835020D1 (de) Plasmabrenner und verwendungsverfahren dieses plasmabrenners
NO963941D0 (no) Rörskjöt med gjenger
EP0759071A4 (en) MONOCLONAL ANTIBODIES AGAINST WT1 AND METHOD FOR THEIR USE
EE04091B1 (et) Koostised ja meetodid silmasisese rõhu alandamiseks
BR9601630A (pt) Uso de uma quantidade eficaz de pelo menos um composto do tipo retinóide e compostos
HUT76781A (en) Mortar for fixing of fixing parts
DE69840871D1 (de) Gerät für multipräzision ganzzahliger arithmetik
NO965075L (no) Dispersjoner av flytpunktsreduserende midler
FI950977A0 (fi) Menetelmä jodattujen varjoaineiden valmistamiseksi ja puhdistamiseksi
EE03783B1 (et) Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine
DE69530992D1 (de) Dispergiermittel für Zement
DE9421091U1 (de) Hülsenanker für Betonteile
KR970016465U (ko) 부품 조립용 체결장치
ITBO940046A0 (it) Protesi articolare interna alleggerita
NO964817D0 (no) Fremgangsmåte for bygging av en rörledning
KR960002700U (ko) 전자사진 응용기기의 수동급지장치
KR970045403U (ko) 복사기의 조도 측정용 지그
HU9401662D0 (en) Mixture of additines for recalling and fixing of latent draulings esspecially dermatogrine markings
KR970014037U (ko) 배기관의 연결용 고정부재
KR970014046U (ko) 배기관의 연결용 고정부재
KR970009188U (ko) 이음방지용 시트벨트의 리드랙터구조
DE69803493T2 (de) Weiches Unterfütterungsmaterial für Zahnprothesen
KR960034876U (ko) 배기파이프 고정용 이음체
KR970003610U (ko) 모니터의 인렛 고정구조

Legal Events

Date Code Title Description
MA Patent expired